Company profile
NASUS PHARMA LTD
AMEX:NSRXBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07868861 | phase1 | recruiting | 2026-09-15 | 2027-01-01 | Nasus Pharma | A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults |
| NCT04696822 | phase1 | completed | 2020-11-01 | 2021-09-28 | Nasus Pharma | Bioavailability of Nasal Epinephrine |
| NCT06205134 | phase1_2 | completed | 2023-08-22 | 2024-02-02 | Nasus Pharma | Comparative Bioavailability of Intranasal Epinephrine |
| NCT07228325 | phase1_2 | enrolling_by_invitation | 2025-11-03 | 2026-03-01 | Nasus Pharma | Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis |
FDA applications (0)
No records yet.